AU2020224401A1 - Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders - Google Patents
Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders Download PDFInfo
- Publication number
- AU2020224401A1 AU2020224401A1 AU2020224401A AU2020224401A AU2020224401A1 AU 2020224401 A1 AU2020224401 A1 AU 2020224401A1 AU 2020224401 A AU2020224401 A AU 2020224401A AU 2020224401 A AU2020224401 A AU 2020224401A AU 2020224401 A1 AU2020224401 A1 AU 2020224401A1
- Authority
- AU
- Australia
- Prior art keywords
- fluoro
- pyridin
- imidazo
- carboxamide
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809230P | 2019-02-22 | 2019-02-22 | |
| US62/809,230 | 2019-02-22 | ||
| PCT/IB2020/051469 WO2020170205A1 (en) | 2019-02-22 | 2020-02-21 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020224401A1 true AU2020224401A1 (en) | 2021-10-14 |
Family
ID=72141573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020224401A Abandoned AU2020224401A1 (en) | 2019-02-22 | 2020-02-21 | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20220242861A1 (https=) |
| EP (2) | EP3927706A4 (https=) |
| JP (2) | JP7609790B2 (https=) |
| KR (2) | KR102892275B1 (https=) |
| CN (2) | CN113454081B (https=) |
| AU (1) | AU2020224401A1 (https=) |
| CA (1) | CA3131059A1 (https=) |
| IL (1) | IL285708B2 (https=) |
| MX (1) | MX2021010122A (https=) |
| WO (2) | WO2020170205A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020224401A1 (en) | 2019-02-22 | 2021-10-14 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
| CN115968362B (zh) * | 2020-08-21 | 2025-06-13 | 第一生物治疗股份有限公司 | 作为pet放射性示踪剂的[18f]-标记的咪唑并吡啶衍生物 |
| US12398156B2 (en) | 2020-08-21 | 2025-08-26 | 1ST Biotherapeutics, Inc. | Compounds for prevention or treatment of neurodegenerative disorders |
| WO2022064459A1 (en) * | 2020-09-28 | 2022-03-31 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods of using same |
| EP4236950A4 (en) * | 2020-10-29 | 2024-10-23 | Merck Sharp & Dohme LLC | N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF |
| WO2022165529A1 (en) * | 2021-02-01 | 2022-08-04 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| CN115724839A (zh) * | 2021-08-26 | 2023-03-03 | 科辉智药生物科技(深圳)有限公司 | Sarm1酶活性抑制剂及其应用 |
| EP4499643A4 (en) * | 2022-03-25 | 2026-01-28 | 1St Biotherapeutics Inc | INDAZOLES USED AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND THEIR METHODS OF USE |
| CN116354959B (zh) * | 2023-03-10 | 2024-04-19 | 石河子大学 | 一种N-N桥连噻唑单元的β-咔啉衍生物及其制备方法、应用 |
| CN121941688A (zh) * | 2023-10-09 | 2026-04-28 | 浙江海正药业股份有限公司 | 多取代芳基类衍生物及其制备方法和用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020084116A (ko) | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| CN101384586A (zh) * | 2006-02-14 | 2009-03-11 | 诺华公司 | Pi-3激酶抑制剂及其应用方法 |
| PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
| EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
| CA2693232A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
| ES2400604T3 (es) * | 2007-08-17 | 2013-04-11 | Icagen, Inc. | Heterociclos como moduladores del canal de potasio |
| AU2008343813B2 (en) * | 2007-12-19 | 2012-04-12 | Amgen Inc. | Inhibitors of PI3 kinase |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| AR071523A1 (es) | 2008-04-30 | 2010-06-23 | Merck Serono Sa | Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento |
| WO2010008847A2 (en) | 2008-06-24 | 2010-01-21 | Takeda Pharmaceutical Company Limited | Pi3k/m tor inhibitors |
| BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
| WO2010100144A1 (en) | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
| US8765747B2 (en) * | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
| NZ598220A (en) * | 2009-08-17 | 2014-02-28 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| EA026115B1 (ru) * | 2010-12-17 | 2017-03-31 | Ф. Хоффманн-Ля Рош Аг | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение |
| WO2014004863A2 (en) * | 2012-06-27 | 2014-01-03 | Alzheimer's Institute Of America, Inc. | Compounds, compositions, and therapeutic uses thereof |
| EP2892534B8 (en) | 2012-09-06 | 2021-09-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| MX365640B (es) | 2012-12-21 | 2019-06-10 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas y sus indicaciones. |
| US9598424B2 (en) * | 2014-03-06 | 2017-03-21 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of TBK1 |
| WO2018017435A1 (en) * | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| WO2018237370A1 (en) * | 2017-06-23 | 2018-12-27 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and method using the same |
| AU2018346051B2 (en) | 2017-10-02 | 2022-11-10 | 1st Biotherapeutics Inc. | Benzothiazol compounds and methods using the same for treating neurodegenerative disorders |
| EP3877371A4 (en) * | 2018-11-07 | 2022-07-27 | Dana-Farber Cancer Institute, Inc. | IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF |
| AU2020224401A1 (en) * | 2019-02-22 | 2021-10-14 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders |
-
2020
- 2020-02-21 AU AU2020224401A patent/AU2020224401A1/en not_active Abandoned
- 2020-02-21 CN CN202080014118.3A patent/CN113454081B/zh active Active
- 2020-02-21 MX MX2021010122A patent/MX2021010122A/es unknown
- 2020-02-21 KR KR1020217030103A patent/KR102892275B1/ko active Active
- 2020-02-21 WO PCT/IB2020/051469 patent/WO2020170205A1/en not_active Ceased
- 2020-02-21 EP EP20759969.7A patent/EP3927706A4/en active Pending
- 2020-02-21 JP JP2021549327A patent/JP7609790B2/ja active Active
- 2020-02-21 US US17/432,497 patent/US20220242861A1/en not_active Abandoned
- 2020-02-21 EP EP20759163.7A patent/EP3927705A4/en active Pending
- 2020-02-21 IL IL285708A patent/IL285708B2/en unknown
- 2020-02-21 US US16/797,140 patent/US11098044B2/en active Active
- 2020-02-21 WO PCT/IB2020/051472 patent/WO2020170206A1/en not_active Ceased
- 2020-02-21 CN CN202080014156.9A patent/CN113454082B/zh active Active
- 2020-02-21 JP JP2021549328A patent/JP2022521537A/ja active Pending
- 2020-02-21 CA CA3131059A patent/CA3131059A1/en active Pending
- 2020-02-21 KR KR1020217030099A patent/KR20210122861A/ko not_active Withdrawn
-
2021
- 2021-07-12 US US17/372,863 patent/US11802126B2/en active Active
-
2023
- 2023-07-19 US US18/223,860 patent/US12534461B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210347774A1 (en) | 2021-11-11 |
| WO2020170205A1 (en) | 2020-08-27 |
| MX2021010122A (es) | 2021-09-23 |
| IL285708A (en) | 2021-10-31 |
| CN113454081A (zh) | 2021-09-28 |
| CN113454082A (zh) | 2021-09-28 |
| IL285708B2 (en) | 2025-02-01 |
| US20200270246A1 (en) | 2020-08-27 |
| US11098044B2 (en) | 2021-08-24 |
| EP3927706A4 (en) | 2022-12-14 |
| JP7609790B2 (ja) | 2025-01-07 |
| US12534461B2 (en) | 2026-01-27 |
| CA3131059A1 (en) | 2020-08-27 |
| KR20210122862A (ko) | 2021-10-12 |
| CN113454082B (zh) | 2024-07-02 |
| US11802126B2 (en) | 2023-10-31 |
| EP3927705A1 (en) | 2021-12-29 |
| KR102892275B1 (ko) | 2025-11-27 |
| KR20210122861A (ko) | 2021-10-12 |
| US20220242861A1 (en) | 2022-08-04 |
| JP2022521536A (ja) | 2022-04-08 |
| JP2022521537A (ja) | 2022-04-08 |
| CN113454081B (zh) | 2024-08-09 |
| US20230365557A1 (en) | 2023-11-16 |
| WO2020170206A1 (en) | 2020-08-27 |
| IL285708B1 (en) | 2024-10-01 |
| EP3927706A1 (en) | 2021-12-29 |
| EP3927705A4 (en) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7609790B2 (ja) | イミダゾピリジニル化合物及び神経変性障害の処置のためのその使用 | |
| WO2016197078A1 (en) | Compounds for the modulation of myc activity | |
| US11744824B2 (en) | 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds | |
| KR102682398B1 (ko) | 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도 | |
| CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
| AU2022238805B2 (en) | Pro drugs of pde10 compounds | |
| RU2833052C2 (ru) | Имидазопиридинильные соединения и их применение для лечения нейродегенеративных расстройств | |
| CN120957987A (zh) | 取代的磺内酰胺化合物衍生物及其药物用途 | |
| EP4200299B1 (en) | Compounds for prevention or treatment of neurodegenerative disorders | |
| HK40058868A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | |
| HK40058868B (zh) | 咪唑并吡啶基化合物及其用於治疗神经退行性疾病的用途 | |
| WO2024222807A1 (en) | Novel macrocyclic heteroaryl derivatives as kinase inhibitors | |
| BR112023018850B1 (pt) | Compostos pde10, composição e usos destes | |
| HK40058867A (en) | Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |